On STAT's podcast, hear about what happened with AbbVie's schizophrenia drug, Amgen's obesity drug and what might happen at ...

Shares in several pharmaceutical and biotechnology companies have fallen since President-elect Trump announced Thursday that ...

Shares of Amazon.com Inc. and Amgen are retreating Friday afternoon, sending the Dow Jones Industrial Average into negative territory.

Researchers have demonstrated that inebilizumab reduced the risk of symptoms by 87 percent in patients with the rare affliction known as immunoglobulin G4-related disease (IgG4-RD).

Dragged down by negative returns for shares of Amgen and Amazon.com Inc., the Dow Jones Industrial Average is declining Friday afternoon.

WASHINGTON -- Patients with IgG4-related disease appeared to benefit from inebilizumab (Uplizna), currently approved for ...

The stocks of companies that make or are developing the new class of weight-loss and diabetes-management drugs were sharply ...

Now, it's up to the European Commission to confirm those potential green lights in the coming weeks and months.

Big Pharma had plenty of drama to keep journalists busy this quarter, which painted an accurate portrait of the wild and ...

(Reuters) -Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a ...

Prevent Blindness has designated November 18 to 24, 2024, as the 5th annual Thyroid Eye Disease (TED) Awareness Week. The ...

Wolfe Research analyst Alexandria Hammond initiated coverage of Amgen (AMGN) with a Peer Perform rating. With the antibody backbone, the firm ...